Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2010

Open Access 01-12-2010 | Research

Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM

Authors: Anthonia O Ogbera, Alfred O Azenabor

Published in: Diabetology & Metabolic Syndrome | Issue 1/2010

Login to get access

Abstract

Background

Lipoprotein (a) (LP (a) is an independent cardiovascular risk factor that is not widely studied in people of sub-Saharan African origin. The aim of this report is to determine the frequency of occurrence of elevated Lp (a) and possible relationship with total cholesterol (TCHOL), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), C reactive protein (CRP) and serum uric acid (SUA).

Methods

This is a cross sectional study carried out in 200 Nigerian patients with type 2 DM and 100 sex and age matched healthy Controls aged between 32-86 years. We determined the frequency of occurrence of elevated Lp (a) levels in the study subjects and compared clinical and biochemical variables between type 2 diabetic patients and non-diabetic patients. Clinical and biochemical parameters were also compared between subjects with type 2 DM who had elevated LP (a) and normal LP (a) levels. Long term glycaemic control using glycosylated haemoglobin was determined and compared in the study subjects. Test statistics used include chi square, correlation coefficient analysis and Student's t test.

Results

The mean Lp(a) concentration differed significantly between type 2 diabetic patients and the Control subjects (18.7 (5.8) mg/dl vs 23 (6.8) mg/dl, 0.00001). Similarly, the prevalence of high LP (a) levels in type 2 DM patients was significantly higher than that of the Control subjects (12.5% vs 4%, p-0.019). The mean levels of the lipid profile parameters (TCHOL, LDL-C, TG, LDL/HDL) and CRP were significantly higher in DM patients than in the Control subjects. The mean LP (a) levels were comparable in both sexes and in DM subjects with and without hypertension. TG was the only parameter that differed significantly between subjects with elevated Lp (a) levels and those with normal Lp (a) levels. There was a significant positive correlation (r) between Lp(a) levels and TG, LDL-C. TCHOL, LDL/HDL and uric acid. No association was found between Lp(a) and clinical parameters such as age and anthropometric indices.

Conclusion

We have showed that Lp (a), CRP and other CVS risk factors cluster more in patients with DM than non DM patients. Serum Lp (a) levels are not associated with anthropometric and glycaemic indices.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ogbera AO: Burden of diabetes mellitus in Nigeria. Trop Doct. 2007, 37 (3): 153-154. 10.1258/004947507781524746.CrossRefPubMed Ogbera AO: Burden of diabetes mellitus in Nigeria. Trop Doct. 2007, 37 (3): 153-154. 10.1258/004947507781524746.CrossRefPubMed
2.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet , Paul Z, Cleeman , James I: Donato Karen Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, Zimmet , Paul Z, Cleeman , James I: Donato Karen Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed
3.
go back to reference Romics L, Karadi I, Csaszar A, Kostner G: Physiological and Clinical Importance of Lipoprotein(a). J Exp Clin Med. 1990, 15: 149-1541. Romics L, Karadi I, Csaszar A, Kostner G: Physiological and Clinical Importance of Lipoprotein(a). J Exp Clin Med. 1990, 15: 149-1541.
4.
go back to reference Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ, Simari RD: "Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis". Blood. 2001, 98 (10): 2980-7. 10.1182/blood.V98.10.2980.CrossRefPubMed Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ, Simari RD: "Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis". Blood. 2001, 98 (10): 2980-7. 10.1182/blood.V98.10.2980.CrossRefPubMed
5.
go back to reference Heller FR, Jamart J Honore P, Derue G, Novik V, Galanti L: Serum lipoprotein (a) in patients with diabetes mellitus. Diabetes Care. 1993, 16 (3): 819-823. 10.2337/diacare.16.5.819.CrossRefPubMed Heller FR, Jamart J Honore P, Derue G, Novik V, Galanti L: Serum lipoprotein (a) in patients with diabetes mellitus. Diabetes Care. 1993, 16 (3): 819-823. 10.2337/diacare.16.5.819.CrossRefPubMed
6.
go back to reference Syed S Habib MA: High risk levels of lipoprotein (a) in Pakistani patients with type 2 diabetes mellitus. Saudi Medical Journal. 2003, 24 (6): 647-651.PubMed Syed S Habib MA: High risk levels of lipoprotein (a) in Pakistani patients with type 2 diabetes mellitus. Saudi Medical Journal. 2003, 24 (6): 647-651.PubMed
7.
go back to reference Li Jin Pu, Lin Lu, Xue Wei Xu, Rui Yn Zhang, Qi Zhang, Jian Sheng Zhang, Hu J, Yang ZK, Ding FH, Chen OJ, Lou S, Shen J, Fang DH, Shen WF: Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovascular Diabetology. 2006, 1475-2840. 5 Li Jin Pu, Lin Lu, Xue Wei Xu, Rui Yn Zhang, Qi Zhang, Jian Sheng Zhang, Hu J, Yang ZK, Ding FH, Chen OJ, Lou S, Shen J, Fang DH, Shen WF: Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovascular Diabetology. 2006, 1475-2840. 5
8.
go back to reference Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, Travia D, Zenti MG, Branzi P, Santi L, Muggeo M: Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. Int J Obes Relat Metab Disord. 1996, 20: 975-80.PubMed Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, Travia D, Zenti MG, Branzi P, Santi L, Muggeo M: Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. Int J Obes Relat Metab Disord. 1996, 20: 975-80.PubMed
9.
go back to reference Lehto S, Niskanem L, Ronnemaa T, Laakso M: Serum uric acid is a strong predictor of stroke in patients with non-insulin dependent diabetes mellitus. Stroke. 1998, 29: 635-9.CrossRefPubMed Lehto S, Niskanem L, Ronnemaa T, Laakso M: Serum uric acid is a strong predictor of stroke in patients with non-insulin dependent diabetes mellitus. Stroke. 1998, 29: 635-9.CrossRefPubMed
10.
go back to reference Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F: Prevalence of hyperuricaemia and relation of serum uric acid in a developing country. BMC Public Health. 2004, 4: 9-10.1186/1471-2458-4-9.PubMedCentralCrossRefPubMed Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F: Prevalence of hyperuricaemia and relation of serum uric acid in a developing country. BMC Public Health. 2004, 4: 9-10.1186/1471-2458-4-9.PubMedCentralCrossRefPubMed
11.
go back to reference Abell LL, Levy BB, Brodie BB, Kendall FE: Simplified methods for the estimation of the total cholesterol in serum and demonstration of specificity. J Biol Chem. 1952, 195: 357-66. Abell LL, Levy BB, Brodie BB, Kendall FE: Simplified methods for the estimation of the total cholesterol in serum and demonstration of specificity. J Biol Chem. 1952, 195: 357-66.
12.
go back to reference Lopez-Virella ML: Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 1977, 23: 882-90. Lopez-Virella ML: Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 1977, 23: 882-90.
13.
go back to reference Bucolo G, David H: Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973, 19: 476-82.PubMed Bucolo G, David H: Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973, 19: 476-82.PubMed
14.
go back to reference Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultra centrifuge. Clin Chem. 1972, 18: 499-502. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultra centrifuge. Clin Chem. 1972, 18: 499-502.
15.
go back to reference Cantrill JA: Diabetes Mellitus. Clinical Pharmacy and Therapeutics. Edited by: Walker R, Edwards C. 1999, Churchill Livingstone, London, 633-52. 2 Cantrill JA: Diabetes Mellitus. Clinical Pharmacy and Therapeutics. Edited by: Walker R, Edwards C. 1999, Churchill Livingstone, London, 633-52. 2
16.
go back to reference King DE, Mainous AG, Buchanan TA, Pearson WS: C-Reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003, 26 (5): 1535-1539. 10.2337/diacare.26.5.1535.CrossRefPubMed King DE, Mainous AG, Buchanan TA, Pearson WS: C-Reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003, 26 (5): 1535-1539. 10.2337/diacare.26.5.1535.CrossRefPubMed
17.
go back to reference Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN: Uric acid and the development of the metabolic syndrome in women and men. Metabolism. 2008, 57 (6): 845-852. 10.1016/j.metabol.2008.01.030.PubMedCentralCrossRefPubMed Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN: Uric acid and the development of the metabolic syndrome in women and men. Metabolism. 2008, 57 (6): 845-852. 10.1016/j.metabol.2008.01.030.PubMedCentralCrossRefPubMed
18.
go back to reference Scherthaner G, Kostner GM, Dieplinger H, Prager R, Muhlhauser I: Apolipoproteins (A-I, A-II, B): lipoprotein(a), lipoproptein and lecithin cholesterol acyl transferase activity in diabetes mellitus. Atherosclerosis. 1983, 49: 277-293. 10.1016/0021-9150(83)90139-9.CrossRef Scherthaner G, Kostner GM, Dieplinger H, Prager R, Muhlhauser I: Apolipoproteins (A-I, A-II, B): lipoprotein(a), lipoproptein and lecithin cholesterol acyl transferase activity in diabetes mellitus. Atherosclerosis. 1983, 49: 277-293. 10.1016/0021-9150(83)90139-9.CrossRef
19.
go back to reference Oyelola OO, Ajayi AA, Babalola RO, Stein EA: Plasma lipids, lipoproteins, and apolipoproteins in Nigerian diabetes mellitus, essential hypertension, and hypertensive-diabetic patients. Natl Med Assoc. 1995, 87 (2): 113-8. Oyelola OO, Ajayi AA, Babalola RO, Stein EA: Plasma lipids, lipoproteins, and apolipoproteins in Nigerian diabetes mellitus, essential hypertension, and hypertensive-diabetic patients. Natl Med Assoc. 1995, 87 (2): 113-8.
20.
go back to reference Guillausseau PJ, Peynet J, Chanson P, Legrand A, Altman JJ, Poupon J: Lipoprotein(a) in diabetic patients with and without chronic renal failure. Diabetes Care. 1992, 15: 976-979. 10.2337/diacare.15.8.976.CrossRefPubMed Guillausseau PJ, Peynet J, Chanson P, Legrand A, Altman JJ, Poupon J: Lipoprotein(a) in diabetic patients with and without chronic renal failure. Diabetes Care. 1992, 15: 976-979. 10.2337/diacare.15.8.976.CrossRefPubMed
21.
go back to reference Ogbera AO, Azenabor AO: Hyperuricaemia and the metabolic syndrome in type 2 DM. Diabetology & Metabolic Syndrome. 2010, 2: 24-doi: 10.1186/1758-5996-2-24CrossRef Ogbera AO, Azenabor AO: Hyperuricaemia and the metabolic syndrome in type 2 DM. Diabetology & Metabolic Syndrome. 2010, 2: 24-doi: 10.1186/1758-5996-2-24CrossRef
22.
go back to reference Ogbera AO: Prevalence and gender distribution of the metabolic Syndrome. Diabetology & Metabolic Syndrome. 2010, 2: 1 doi: 10.1186/1758-5996-2-1. Ogbera AO: Prevalence and gender distribution of the metabolic Syndrome. Diabetology & Metabolic Syndrome. 2010, 2: 1 doi: 10.1186/1758-5996-2-1.
23.
go back to reference Perez A, Carreras G, Caixas A, Castellvi A, Caballero A, Bonet R, Ordonezlianos J: Plasma lipoprotein(a) levels are not influenced by glycaemic control in type 1 diabetes. Diabetes Care. 1998, 21: 1517-1520. 10.2337/diacare.21.9.1517.CrossRefPubMed Perez A, Carreras G, Caixas A, Castellvi A, Caballero A, Bonet R, Ordonezlianos J: Plasma lipoprotein(a) levels are not influenced by glycaemic control in type 1 diabetes. Diabetes Care. 1998, 21: 1517-1520. 10.2337/diacare.21.9.1517.CrossRefPubMed
Metadata
Title
Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM
Authors
Anthonia O Ogbera
Alfred O Azenabor
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2010
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-2-51

Other articles of this Issue 1/2010

Diabetology & Metabolic Syndrome 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.